Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Acquisition Is Associated With Individual Exposure but Not Community-Level Transmission.
Friedman-Klabanoff DJ, Fitzpatrick MC, Deming ME, Agrawal V, Sitar S, Schaafsma T, Brown E, Neuzil KM, Barnabas RV, Laufer MK; Hydroxychloroquine COVID-19 Postexposure Prophylaxis Study Team. Friedman-Klabanoff DJ, et al. J Infect Dis. 2022 Aug 24;226(2):225-235. doi: 10.1093/infdis/jiac029. J Infect Dis. 2022. PMID: 35134185 Free PMC article. Clinical Trial.
Epitope-Specific Antibody Responses to a Plasmodium falciparum Subunit Vaccine Target in a Malaria-Endemic Population.
Friedman-Klabanoff DJ, Travassos MA, Ifeonu OO, Agrawal S, Ouattara A, Pike A, Bailey JA, Adams M, Coulibaly D, Lyke KE, Laurens MB, Takala-Harrison S, Kouriba B, Kone AK, Doumbo OK, Patel JJ, Thera MA, Felgner PL, Tan JC, Plowe CV, Berry AA. Friedman-Klabanoff DJ, et al. J Infect Dis. 2021 Jun 4;223(11):1943-1947. doi: 10.1093/infdis/jiaa611. J Infect Dis. 2021. PMID: 32992328 Free PMC article.
Safety and immunogenicity of AGS-v PLUS, a mosquito saliva peptide vaccine against arboviral diseases: A randomized, double-blind, placebo-controlled Phase 1 trial.
Friedman-Klabanoff DJ, Birkhold M, Short MT, Wilson TR, Meneses CR, Lacsina JR, Oliveira F, Kamhawi S, Valenzuela JG, Hunsberger S, Mateja A, Stoloff G, Pleguezuelos O, Memoli MJ, Laurens MB. Friedman-Klabanoff DJ, et al. EBioMedicine. 2022 Dec;86:104375. doi: 10.1016/j.ebiom.2022.104375. Epub 2022 Nov 24. EBioMedicine. 2022. PMID: 36436281 Free PMC article. Clinical Trial.
Estimated COVID-19 vaccine effectiveness against seroconversion from SARS-CoV-2 Infection, March-October, 2021.
Plumb ID, Fette LM, Tjaden AH, Feldstein L, Saydah S, Ahmed A, Link-Gelles R, Wierzba TF, Berry AA, Friedman-Klabanoff D, Larsen MP, Runyon MS, Ward LM, Santos RP, Ward J, Weintraub WS, Edelstein S, Uschner D. Plumb ID, et al. Vaccine. 2023 Apr 6;41(15):2596-2604. doi: 10.1016/j.vaccine.2023.03.006. Epub 2023 Mar 9. Vaccine. 2023. PMID: 36932031 Free PMC article.
Factors associated with COVID-19 vaccination during June-October 2021: A multi-site prospective study.
Datar RS, Fette LM, Hinkelman AN, Hammershaimb EA, Friedman-Klabanoff DJ, Mongraw-Chaffin M, Weintraub WS, Ahmed N, Gibbs MA, Runyon MS, Plumb ID, Thompson W, Saydah S, Edelstein SL, Berry AA; COVID-19 Community Research Partnership. Datar RS, et al. Among authors: friedman klabanoff dj. Vaccine. 2023 May 11;41(20):3204-3214. doi: 10.1016/j.vaccine.2023.03.057. Epub 2023 Mar 31. Vaccine. 2023. PMID: 37069033 Free PMC article.
Serologic responses to the PfEMP1 DBL-CIDR head structure may be a better indicator of malaria exposure than those to the DBL-α tag.
Stucke EM, Niangaly A, Berry AA, Bailey JA, Coulibaly D, Ouattara A, Lyke KE, Laurens MB, Dara A, Adams M, Pablo J, Jasinskas A, Nakajima R, Zhou AE, Agrawal S, Friedman-Klabanoff DJ, Takala-Harrison S, Kouriba B, Kone AK, Rowe JA, Doumbo OK, Felgner PL, Thera MA, Plowe CV, Travassos MA. Stucke EM, et al. Among authors: friedman klabanoff dj. Malar J. 2019 Aug 13;18(1):273. doi: 10.1186/s12936-019-2905-9. Malar J. 2019. PMID: 31409360 Free PMC article.
Low dose recombinant full-length circumsporozoite protein-based Plasmodium falciparum vaccine is well-tolerated and highly immunogenic in phase 1 first-in-human clinical testing.
Friedman-Klabanoff DJ, Berry AA, Travassos MA, Cox C, Zhou Y, Mo AX, Nomicos EYH, Deye GA, Pasetti MF, Laurens MB. Friedman-Klabanoff DJ, et al. Vaccine. 2021 Feb 22;39(8):1195-1200. doi: 10.1016/j.vaccine.2020.12.023. Epub 2021 Jan 22. Vaccine. 2021. PMID: 33494963 Free PMC article. Clinical Trial.
Recombinant full-length Plasmodium falciparum circumsporozoite protein-based vaccine adjuvanted with GLA-LSQ: Results of Phase 1 testing with malaria challenge.
Friedman-Klabanoff DJ, Berry AA, Travassos MA, Shriver M, Cox C, Butts J, Lundeen JS, Strauss KA, Joshi S, Shrestha B, Mo AX, Nomicos EYH, Deye GA, Regules JA, Bergmann-Leitner ES, Pasetti MF, Laurens MB. Friedman-Klabanoff DJ, et al. J Infect Dis. 2024 Feb 8:jiae062. doi: 10.1093/infdis/jiae062. Online ahead of print. J Infect Dis. 2024. PMID: 38330357
12 results